Cardio Diagnostics Holdings, Inc. (CDIO)
- Previous Close
2.0150 - Open
2.0500 - Bid 1.4600 x 200
- Ask 2.6700 x 200
- Day's Range
1.9800 - 2.0900 - 52 Week Range
0.9700 - 7.9100 - Volume
25,114 - Avg. Volume
58,732 - Market Cap (intraday)
6.008M - Beta (5Y Monthly) 2.23
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9000 - Earnings Date (est.) Nov 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
cdio.ai15
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News
View MorePerformance Overview
Trailing total returns as of 2026-09-11, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreStatistics
View MoreValuation Measures
Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (5yr expected)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.06%
Return on Equity (ttm)
-75.44%
Revenue (ttm)
14.45k
Net Income Avi to Common (ttm)
-6.47M
Diluted EPS (ttm)
-2.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.59M
Total Debt/Equity (mrq)
4.98%
Levered Free Cash Flow (ttm)
-3.77M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
